Cephalon, Inc. v. Abraxis Bioscience, LLC, No. 14-1411 (Fed. Cir. June 17, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Plaintiffs-appellants Acusphere, Inc. and Cephalon, Inc. (collectively, “Acusphere”) appeal certain claim construction determinations of the United States District Court for the District of Massachusetts with respect to a patent directed to formulations of, and methods of making, the anticancer drug product paclitaxel. In light of the district court’s construction, Acusphere stipulated to a final judgment of non- infringement. Defendants - cross-appellants Abraxis Bioscience, LLC and Celgene Corp.